Bristol-Myers Squibb
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bristol-Myers Squibb sits in the top decile of US sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count).
Bristol-Myers Squibb: 1,025 sponsored US clinical trials, 73 recruiting.
Bristol-Myers Squibb sponsors 1,025 registered US clinical trials on ClinicalTrials.gov, 73 of them currently recruiting, and 789 completed. 242 of these trials are in Phase 3-4 (later-stage) and 675 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 20 trials.
Top-decile sponsor footprint
Bristol-Myers Squibb ranks in the top decile of sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
789 of 892 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,025 total, page 19 of 21
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
NCT00123474
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
NCT00123487
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
NCT00124982
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
NCT00198289
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
NCT00162253
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
NCT00256750
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
NCT00103844
Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients
NCT00124449
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
NCT00101660
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
NCT00114777
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
NCT00095147
A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators
NCT00162448
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
NCT00101608
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT00101595
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
NCT00096785
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
NCT00101816
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
NCT00101647
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
NCT00104130
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
NCT00162097
Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects
NCT00096746
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension
NCT00095550
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
NCT00097357
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
NCT00207025
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
NCT00135434
A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen
NCT00135447
Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
NCT00095290
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
NCT00094653
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
NCT00207103
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
NCT00095758
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
NCT00095394
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
NCT00279734
Phase I (PH I) Mad Refractory Solid Tumor Study
NCT00099606
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
NCT00084253
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
NCT00095823
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
NCT00084656
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
NCT00094991
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
NCT00135395
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
NCT00113191
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
NCT00135343
BMS-599626 in Patients With Advanced Solid Malignancies
NCT00095537
A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients
NCT00002207
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
NCT00095030
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
NCT00120393
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
NCT00095173
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
NCT00103701
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
NCT00240370
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
NCT00065507
PPAR-COMBO With Sulfonylurea
NCT00162175
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00729950
PPAR - Combination With Metformin
NCT00162240
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 436 |
| Phase 2 | 239 |
| Phase 3 | 213 |
| Phase 4 | 29 |
Therapeutic Areas
What is open in the Bristol-Myers Squibb pipeline
73 recruiting of 1,025 indexed (7% open); 789 completed (77%).
Phase mix: 242 late (III/IV) vs 675 early (I/II) (early-phase heavy).
Top condition: HIV Infections (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bristol-Myers Squibb: open-pipeline peers nationwide
Peers matched on 1,025 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,025 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- University of Washington · 1,048 trials · 15% recruiting
- University of Minnesota · 966 trials · 19% recruiting
- Columbia University · 958 trials · 18% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
Related
What to do with this Bristol-Myers Squibb page
1,025 registered trials is a research-attention snapshot, not an endorsement of Bristol-Myers Squibb or any single study.
- 73 of Bristol-Myers Squibb's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition Bristol-Myers Squibb studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bristol-Myers Squibb pipeline card: 1,025 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.